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Dexmedetomidine is an α2 adrenergic agonist which has recently been approved in the United States for procedural sedation in
adults. This report describes an infant who inadvertently received an intravenous infusion of dexmedetomidine at a rate which
was 60 times greater than intended. We describe the hemodynamic, respiratory, and sedative eﬀects of this overdose.
1.Introduction
Infants and children frequently require sedation in order
to ensure motionless conditions for radiological imaging
studies. At our institution, dexmedetomidine (Precedex;
Hospira, Lake Forest, IL) is the standard sedative, approved
by the Hospital Sedation Committee and Pharmacy and
therapeutics Committee for MRI studies. Dexmedetomidine
is a highly selective α2 adrenoceptor agonist that possesses
both sedative and analgesic eﬀects [1]. Recently approved
by the Food and Drug Administration (FDA) for procedural
sedation, dexmedetomidine approval is still limited to adults
only. In children, when dexmedetomidine is used as a sole
agent for sedation, the doses needed to achieve adequate
sedation have been shown to be remarkably high and exceed
those approved for use by the FDA [2].
Thepotentialhemodynamiceﬀectsofdexmedetomidine,
notably sympatholysis due to α2 agonism at sympathetic
ganglia, have been well described in healthy adults [3].
Bradycardia, hypotension, and the potential for hyperten-
sion have all been described when dexmedetomidine is
administered to adults [4, 5]. The hemodynamic eﬀects of
dexmedetomidine in children, particularly when adminis-
tered in greater than approved dosages, still remain to be
clearly deﬁned. Some series have reported that at higher
dosages there is bradycardia and a tendency towards blood
pressure variability [2, 6, 7]. The dosages required to
accomplishMRIsedationwithdexmedetomidinerangefrom
2 to 3mc/kg bolus and an infusion of 1-2mcg/kg/hr [2, 6, 8].
The only case report in the literature of a dexmedetomi-
dine overdosage in a child describes an elevated blood pres-
sure and an extended recovery period [9]. Our case report
describes a diﬀerent sedative and hemodynamic response
when an infant received an inadvertent administration of
dexmedetomidine at an infusion rate of 60 times that
prescribed for 20 minutes.
2.CaseReport
A 21-month-old female with recent history of two febrile
seizures (30 minutes apart) presented for an outpatient
MR imaging study of the brain to complete the neuro-
logical evaluation. The infant was an otherwise healthy,
full-term baby, and with an unremarkable medical history
and review of systems. Upon presentation, the patient was
not taking any medications although her mother carried
Diastat (Acudial. Diazepam, Valeant Pharmaceuticals. Costa
Mesa, CA) in the event the seizure recurred. The 9.9kg
infant presented in a calm, nonagitated state with a heart
rate (HR) of 110beats/minute, respiratory rate (RR) of
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(NIBP) measurement of 85/60 with a mean arterial pressure
(MAP) of 68 and a room air oxygen saturation of 100%.
After careful review of the infant, discussion with the
mother, and a physical examination, the dexmedetomi-
dine was ordered per protocol by the pediatric nurse
practitioner under the supervision of an anesthesiologist.
Written, informed consent was obtained from the mother
for the dexmedetomidine sedation. A 24-gauge intravenous
catheter was initiated and dexmedetomidine was ordered per
protocol, specifying a bolus of 2mcg/kg over 10 minutes
and a subsequent infusion of 1mcg/kg/hr. The bolus was
administered at the ordered rate of 2mcg/kg over a period
of 10 minutes using an Iradimed 3850mRidium MR IV
pump (Iradimed Corp, Winter Park, Fla). Vital signs (NIBP,
MAP, 3-lead EKG, pulse oximeter, and HR) were monitored
continuously using an Invivo Precess monitor (Invivo Corp,
Orlando, and Fla) and documented every ﬁve minutes.
The patient achieved successful sedation conditions (Ramsay
Sedation Score = 4) by the completion of the bolus. Upon
completion of this 10-minute bolus, NIBP was 118/79 (MAP
92), HR 77 (normal sinus), RR 17, and oxygen saturation of
97% on 2 liters/min oxygen via nasal canula (see Figure 1).
Sedation guidelines at our institution specify supplemental
oxygendeliverythroughoutthesedationandrecoveryperiod
until discharge criteria are met. Following the bolus, the
infusion pump initiated delivery of the dexmedetomidine
infusion at the rate that had been programmed in at the
initiation of the sedation. The dexmedetomidine infusion
was continued throughout the sedation until the MRI scan
wascomplete.Thepatientremainedhemodynamicallystable
throughout Vital signs were documented at ﬁve-minute
intervals per our hospital standard for sedation, following
initiation of this dexmedetomidine infusion (Table 1).
At the termination of the study, the radiology nurse
noted that the dexmedetomidine remaining in the syringe
was less than anticipated and medication reconciliation was
immediately initiated with a second nurse. Reconciliation
revealed that the 9.9-kg infant had received 196mcg more
dexmedetomidine than had been ordered. Review of the
intravenous infusion pump revealed that the pump had
been misprogrammed to deliver the infusion at a rate
of mcg/kg/min rather than mcg/kg/hr. Thus, instead of
delivering the usual 1mcg/kg/hour as ordered, the infusion
pump delivered the dose at 1mcg/kg/minute (equivalent to
60mcg/kg/hr). Because this error was not identiﬁed during
the mandatory institutional nursing “double check” when
the infusion pump was programmed, the error was not
identiﬁed,andthedexmedetomidineinfusionwascontinued
for the 20 minutes.
Following the imaging study, the patient was transferred
uneventfully to the radiology recovery room at which
time monitoring was continued. The patient arrived in
the recovery room deeply sedated with an RSS 4. Per
recovery room policy, NIBP, MAP, EKG, HR, O2 Sat,
and RR are documented every 5 minutes until modi-
ﬁed Aldrete discharge criteria are met [10]. A minimum
Aldrete score for discharge from the recovery room is 9.
Although documented every 5 minutes, pulse oximetry is
monitored continuously. Throughout the recovery room
course, all physiologic parameters remained within age-
adjusted normal values. 20 minutes after the discontinuation
of the dexmedetomidine, the infant had achieved a modiﬁed
Aldrete score of 9 and maintained an Aldrete of 9-10
throughout the remainder of the recovery room stay. No
cardiac arrhythmias were noted at any time, both during the
sedation as well as in the recovery room period. As soon
as the error in dosing was identiﬁed, Risk Management was
notiﬁed and the parents were debriefed and all questions
answered by the Risk Management team as well as the super-
vising anesthesiologist. The parents were informed that the
intravenous infusion pump had been misprogrammed and
that the child had received an infusion of 60 times that which
was ordered and intended. The eﬀects of such a high dosage
of dexmedetomidine delivery to an infant had not to date
been described nor documented. In adults, the distribution
half-life (t1/2) is approximately 6 minutes and the terminal
elimination half-life (t1/2) is approximately 2 hours [11].
The infant returned to baseline neurological status, an
Aldrete Score of 10, after a 2-hour recovery room period.
Althoughthehalf-lifeofdexmedetomidineisrelativelyshort,
and the child met discharge criteria with a modiﬁed Aldrete
Score of 10 within hours of discontinuing the dexmedeto-
midine, the physicians chose to admit her to the hospital
for overnight, continuous cardiorespiratory monitoring.
Subsequently, the patient was admitted to the intensive care
unit (ICU) for overnight monitoring of EKG as well as pulse
oximetry, blood pressure, and neurological status. The child
remained hemodynamically and neurologically stable in the
ICU throughout the night. There were no arrhythmias, no
change in neurologic status nor any deviation in heart rate
or blood pressureoutside of age-adjustedanticipated normal
values. The next morning, after reassessment by neurology
and the intensive care unit service, the infant was discharged
home with no subsequent sequela.International Journal of Pediatrics 3
Table 1: Vital Signs at time points (minutes) prior to, during, and following initiation of the dexmedetomidine bolus and infusion.
Presedation/Baseline 0 5 10 15 20 25 30 35 40 45
NIBP 85/60 118/79 123/85 143/87 126/82 122/84 127/86 124/72 117/79 107/67 106/57
MAP (mmHg) 68 92 100 108 103 95 95 89 88 76 68
Heart Rate (BPM) 110 77 75 78 82 85 79 85 89 93 90
RR (breaths/min) 20 17 13 24 13 14 14 16 18 18 18
O2 Saturation 100% 97% 96% 96% 96% 97% 97% 98% 98% 99% 99%
EKG NSR NSR NSR NSR NSR NSR NSR NSR NSR NSR NSR
NSR: Normal Sinus Rhythm
MAP: noninvasive mean arterial blood pressure
RR: Respiratory rate
0–10 minutes: The dexmedetomidine bolus administered
10–20 minutes: The dexmedetomidine infusion initiated and completed
20–45 minutes: The recovery room period until discharge criteria, deﬁned as a minimum modiﬁed Aldrete Score 9, are achieved.
3. Discussion
Dexmedetomidine (Precedex) is a relatively selective α2-
adrenergic agonist with sedative properties. As an imidazole,
dexmedetomidine has an α2:α1 activity ratio of 1620:1,
compared to 220:1 with clonidine [12]. It is known
that spinal and supraspinal α2-adrenoreceptors mediate
and modulate nociception. These receptors are widely
distributed throughout the peripheral and central nervous
systems and a variety of organs, including liver, kidney,
and pancreas. α2-adrenoreceptors have been located at
presynaptic, postsynaptic, and extrasynaptic sites. Of these,
the presynaptic and postsynaptic receptors may be the more
clinically important in analgesia. In general, activation of
α2-presynapticreceptorsinhibitsnorepinephrinereleaseand
possibly substance P release, thereby inhibiting pain signal
transmission. Postsynaptic activation in the central nervous
system inhibits sympathetic activity, thus moderating heart
rate and blood pressure [13–18]. Together, these eﬀects
produce analgesia, sedation, and anxiolysis.
Recently approved (October 2008) for procedural seda-
tion outside of the intensive care unit setting, Dexmedeto-
midine is still not approved by the Food and Drug Adminis-
tration (FDA) for pediatric use. Although not approved in
children, its use has been described for pediatric sedation
in the intensive care unit, for radiology, gastroenterology,
and dental procedures, as well as for electroencephalograms
[19–28]. The dosages required to achieve sedation in infants
and children tend to be higher than for adults. The need
for higher dosages in children as compared to adults is
conﬁrmed in a recent pharmacokinetic study [29].
In adults, dexmedetomidine can produce varying depths
of sedation which have been compared to states of natural
sleep with respect to cardiovascular and respiratory eﬀects
[1]. When administered to adults within clinical dosing
guidelines, there are no demonstrated signiﬁcant accompa-
nying changes in resting ventilation [3, 30, 31]. In fact, there
is an evidence to support that dexmedetomidine actually
mimics some aspects of natural sleep in both children and
adults [30, 32].
Our concern with this infant following the overdosage
was the potential for hemodynamic compromise. In both
adults and children, there may be an increased incidence
of clinically signiﬁcant bradycardia with hypotension and
possibly even cardiac arrest with dexmedetomidine, espe-
cially when administered with other medications which
possess negative inotropic or chronotropic eﬀects [33]. The
potentialhemodynamiceﬀectsofdexmedetomidine,notably
sympatholysis, have shown a biphasic physiologic response
characterized by an initial increase in systolic blood pressure
and a reﬂex-induced decrease in heart rate followed by
stabilization of heart rate and blood pressure below baseline
values. The initial increase in MAP reportedly lasts for 5–
10 minutes with a subsequent decrease in MAP of approx-
imately 10%–20% below baseline with an HR that usually
stabilizes below baseline values. These eﬀects have been
attributedtoaninhibitionofthecentralsympatheticoutﬂow
[30, 34]. Hemodynamic variability with dexmedetomidine
has been described in case reports of severe bradycardia
in a child with digoxin, hypertension in a child with
traumatic brain injury, and hypertension in a child with
acute transverse myelitis [5, 35, 36]. Children who received
dexmedetomidine (3mcg/kg bolus and 2mcg/kg infusion)
are more likely to manifest hypertension if they are less than
o n ey e a ro fa g ea n dh a v er e c e i v e dm o r et h a no n eb o l u so f
dexmedetomidine [7].
At our institution, radiology sedation is administered
by nurses under the direct supervision of a pediatric nurse
practitioner and supervising anesthesiologist. All children
must be medically appropriate to receive dexmedetomidine
sedation and cannot have any conditions which our insti-
tutional Hospital Sedation Committee considers to be a
contraindication to dexmedetomidine [2, 6, 8]( Table 2).
Dexmedetomidine sedation is administered following pro-
tocols which are on preprinted, templated order sheets
approved by the Pharmacy and Therapeutics Commit-
tee. The order sheet speciﬁes the following. A bolus of
dexmedetomidine is administered at a speciﬁed dose in
mcg/kg over 10 minutes. The goal of the bolus is to achieve
a minimum Ramsay Sedation Score (RSS) 4 [37]. An RSS
4 or RSS 5 is a clinically derived scoring system that is
generally accepted as the depth of sedation adequate to
facilitate diagnostic imaging studies [8, 38]. This bolus may
berepeatedatthesamedosageandtimeintervalifthepatient4 International Journal of Pediatrics
Table 2: Medical Conditions Which Contraindicate Dexmedetomidine Sedation.
Active, uncontrolled gastroesophageal reﬂux—an aspiration risk
Active, uncontrolled vomiting—an aspiration risk
Current (or within past 3 months) history of apnea requiring an apnea monitor
Active, current respiratory issues that are diﬀerent from the baseline status (pneumonia, exacerbation of asthma, bronchiolitis,
and respiratory synctitial virus)
Unstable cardiac status (life threatening arrhythmias, abnormal cardiac anatomy, and signiﬁcant cardiac dysfunction)
Craniofacial anomaly, which could make it diﬃcult to eﬀectively establish a mask airway for positive pressure ventilation if
needed




fails to achieve or maintain the minimum RSS 4, at any time
during the sedation. Following completion of the bolus, and
conﬁrmation of adequate sedation, an infusion at a speciﬁed
dosage in mcg/kg/hr is immediately started and continued
until completion of the study. Following completion of the
MR scan, the dexmedetomidine is discontinued, the patient
istransportedtotheradiologyrecoveryroomandmonitored
with documentation of vital signs every 5 minutes until
discharge criteria are met. Per our institutional guidelines,
discharge criteria require a minimum Aldrete Score of 9
points [10].
In summary, this report describes the outcome dur-
ing and following a substantial, inadvertent overdosage of
dexmedetomidine to an infant. The overdosage represents a
continuous dexmedetomidine infusion for 20 minutes at a
rate which was almost 80 times that was recommended by
the Food and Drug Administration for adults. To date, most
of the reports of inadvertent overdosage are in adults, with
the degree of overmedication substantially less than cited
in our report [39]. The child received 60mcg/kg/hour for
20 minutes and maintained cardiovascular and respiratory
stability. Our experience diﬀers from a previous overdose
report which described an increase in blood pressure [9].
The absence of a signiﬁcant hypertensive response suggests
thatinfantsmaynotdemonstratethebiphasichemodynamic
response for blood pressure and vascular resistance as is
reported in the adult literature [40]. This report is important
because it demonstrates that even in excessive dosages,
dexmedetomidine may not elicit an extreme hemodynamic
or respiratory eﬀect. This child exhibited a prolonged
recovery and somnolence, with almost 2 hours to meet
Aldrete discharge criteria. This prolonged recovery period is
longer than the average 30 minutes recovery time, when the
prescribed dosage is administered [2].
Although the infant in this report did not suﬀer any
noticeable short- or long-term adverse sequela, our experi-
ence, however, identiﬁes a serious and important mishap;
Dexmedetomidine is unusual in that it is administered
as an infusion with an hourly rate rather than a rate
expressed per minutes. Both nursing and physicians are
more commonly habituated to administer infusions per
minute. Thus, careful double checks of the programmed
r a t em u s tb ef o l l o w e di no r d e rt oe n s u r ea c c u r a t ed e l i v e r y
of dexmedetomidine. There are no clear guidelines from
the Joint Commission for the programming and delivery
of intravenous medication. Rather, standard practice in our
institution requires that the accurate programming of the
infusion pump be independently veriﬁed by two separate
nurses.Evenwiththisprocessinplaceanddocumentationby
two separate nurses that each had independently performed
and veriﬁed the drug concentration, bolus and infusion
dosage, and rate of administration, the error occurred.
As a result of this incident, our institution has added an
additional safety measure. The dexmedetomidine program
in the infusion pump has been restricted to deliver infusions
in units of mcg/kg/hour and a bolus in units of mcg/kg. The
ability to deliver dexmedetomidine at a mcg/kg/minute rate
or mg/kg dosage has been lockedout.
In conclusion, despite a large overdose of dexmedeto-
midine, this infant demonstrated hemodynamic stability
throughout without incidence of hypotension or hyper-
tension. Aside from the prolonged sedation for up to 2
hours following discontinuation of the infusion, she suﬀered
no additional sequela. This report reveals the need for
continued study of dexmedetomidine in order to determine
the optimal dosing to ensure successful sedation conditions,
hemodynamic stability, and a safe recovery period.
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